How do you consider infectious risk from COVID-19 in your choice for frontline treatment of low-grade advanced-stage follicular lymphoma?
How do you decide between chemoimmunotherapy (eg. BR) vs non-chemotherapy-based regimens (eg. R2)?
Are you routinely incorporating anti-COVID-19 monoclonal antibodies (Evusheld) into your treatment plans for these patients?